Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01418209 · ClinicalTrials.gov registry record · NA
MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 339
- Enrollment target
NCT01418209 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 339 participants.
The verdict
NCT01418209, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 339 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17-ß-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes. Included in this objective is the intention to compare venlafaxine XR to estradiol therapy, to provide evidence of the relative efficacy of venlafaxine to what is currently considered the most established but also a controversial therapy. 17-ß-estradiol is a type of estrogen. Venlafaxine XR is the extended release (XR) version of venlafaxine. Venlafaxine XR is an serotonin-norepinephrine reuptake inhibitor (SNRI). A placebo is a substance containing no medication.
Interventions
- DRUG Placebo
- DRUG Venlafaxine XR
- DRUG Low-dose 17-ß-estradiol with progesterone taper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 339 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01418209
The ClinicalTrials.gov registry entry for NCT01418209 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 339 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01418209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01418209 about?
NCT01418209 is a clinical study titled "MsFLASH-03: Comparative Efficacy of Low-Dose Estradiol and Venlafaxine XR for Treatment of Menopausal Symptoms". The primary objective of this study is to determine the efficacy of both low-dose oral (by mouth) 17-ß-estradiol and the non-hormonal drug venlafaxine XR compared to placebo in reducing hot flashes. Included in this objective is the intention to compare venlafaxine XR to estradiol therapy, to provid...
What is the current status of trial NCT01418209?
This trial is currently completed. It is a NA study. The enrollment target is 339 participants. The study started on 2011-11. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01418209?
The interventions under investigation include: Placebo (DRUG), Venlafaxine XR (DRUG), Low-dose 17-ß-estradiol with progesterone taper (DRUG).
Who is sponsoring clinical trial NCT01418209?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.